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Abstract 
 
Chikungunya virus (CHIKV) is a single-stranded positive sense RNA mosquito borne 
alphavirus. In humans, this virus results in debilitating arthritis accompanied by fever, rash, 
myalgia, and headache. At this time, CHIKV has no licensed vaccines or approved specific 
treatments except for symptomatic relief such as NSAIDs to decrease inflammation. Thus far, the 
genome sequence of CHIKV and the proteins it encodes have been well studied, but the role the 
RNA secondary structure itself and the impact it has on viral replication and pathogenesis is less 
understood. Using SHAPE-MaP analysis, eighteen novel, highly stable RNA structures have been 
identified in the coding region of the CHIKV genome. To understand the function of these 
structures, we systematically disrupted each by introducing mutations that change their structure 
while maintaining codon usage and tested both the infectivity of the naked RNA through specific 
infectivity assays and viral replication through growth curves.  
  At this time these structural mutants have not shown an impact on RNA infectivity or viral 
replication compared to that of a wild type vaccine strain of CHIKV (181/25) in mosquito or 
mammalian cells; however, further characterization in additional immune competent cell lines is 
required to fully understand the impact that these structures have on viral replication, pathogenesis, 
and host range. By defining the role that the novel RNA structures play in the lifecycle and 
pathogenesis of the CHIKV virus, it may expand the possible targets for CHIKV therapies and 
vaccines. 
 
Introduction  
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 Chikungunya virus (CHIKV) is a single-stranded positive sense RNA mosquito borne 
alphavirus. The CHIKV genome is 12kB long and contains two open reading frames, which 
produce both structural and nonstructural proteins1. CHIKV causes severe prolonged debilitating 
arthritis in humans, which is accompanied by fever, rash, myalgia, and headache1. In 2004, an 
outbreak in Kenya spread to India and parts of Southeast Asia, resulting in an estimated 6 million 
cases of the disease. In 2013, CHIKV transmission was reported for the first time in the Western 
Hemisphere, and since then over 2 million cases spanning almost 50 countries globally have been 
reported1. At this time, CHIKV has no approved licensed vaccines or specific treatments except 
for symptomatic relief, such as NSAIDs, to decrease inflammation. With the lack of a vaccine or 
specific treatment options, CHIKV poses a serious public health concern since the resulting 
debilitating and chronic arthritis severely impacts an individual’s quality of life and may incur 
substantial healthcare costs.  
Current research on CHIKV treatment options has focused on antivirals that disrupt the 
viral proteins needed for replication and pathogenesis. Further, the genome sequence of CHIKV 
and the proteins encoded have been well studied. However, little work has been done to determine 
the role of the viral RNA secondary structure itself nor the impact that such RNA structures have 
on viral replication, and the extent to which these RNA secondary structures are involved in 
infectivity, replication, and thereby pathogenesis is currently unknown. This project investigates 
the role that novel, stable RNA structures in the CHIKV genome play in the viral life cycle, 
specifically in the virus’s replication process. This is significant because it may expand the possible 
targets for CHIKV therapies and vaccines. Further, targeting these RNA structures necessary for 
replication and pathogenesis during vaccine development, may reduce the risk of virus – induced 
disease caused by live attenuated viruses. By examining how CHIKV RNA structures impact the 
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virus’s life cycle and pathogenesis, we can develop strategies for investigating other alphaviruses 
as well as other single stranded, positive sense RNA viruses and advance our knowledge of viral 
pathogenesis and effective treatment options.   
To determine the stable RNA secondary structures in the CHIKV genome, SHAPE-MaP 
was performed. This analysis uses 2’-hydroxyl-selective reagents that form covalent 2’-O-adducts 
at confirmationally flexible RNA molecules; areas that have high reactivity are typically not 
involved in base pairing, while low reactivity areas are2. Reverse transcriptase then misreads these 
modified nucleotides, causing a noncomplementary nucleotide to be incorporated into the cDNA2. 
This cDNA is sequenced and compared to a reference sequence to create a mutational profile which 
is then normalized to produce a SHAPE reactivity profile. This reactivity profile allows us to 
identify areas in the genome that are involved in base pairing to form secondary structures. By 
combining these reactivity plots with base pairing and entropy data, and incorporating RNA 
secondary structure prediction algorithms3, it is possible to predict and model secondary structures. 
In this study, we used SHAPE-MaP analysis to identify 18 novel, highly stable structures 
that were not previously described. We systematically disrupted each of these individual RNA 
structures using mutations in the genome to measure the impact the altered RNA structure has on 
the virus’s replication mechanisms in insect and mammalian cells through specific infectivity 
assays and virus growth curves. By understanding the impact these structures have on virus’s 
ability to replicate, this project aims to assist in developing an understanding of the impact of RNA 
structures on the overall life cycle, pathogenesis, and host range of CHIKV and other single 
stranded RNA viruses. In the current sense, our data suggests that none of the RNA structure 
mutants are involved in basic virus replication in mammalian and insect cells. Future studies are 
needed to test if these RNA secondary structures interact with innate immune system in 
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mammalian and insect cells or if these RNA structure mutants impact the virus’s ability to compete 
with wildtype or another structure mutant.  
Methods 
Mutating Infectious Clone System 
To understand the impact that these RNA secondary structures have on viral replication, 
we made mutations using an infectious clone system. Restriction enzymes AgeI and SwaI flank 
the area of the genome we wanted to mutate, which SHAPE-MaP analysis indicated contained 
stable RNA secondary structures in the viral RNA, to disrupt the RNA structure.  To create gene 
alterations, gene blocks containing the desired mutations were ligated into AgeI/SwaI (NEB) 
digested 181/25 viral plasmid backbone (vaccine strain of CHIKV). The resulting ligated plasmids 
were transformed into chemically competent E.coli cells (NEB) and plated onto agar plates with 
carbinicillin (100µg/µL) to obtain single colonies. The single colonies were grown overnight to 
amplify the plasmid and the plasmid DNA was isolated and purified using Qiagen Mini-Prep 
kit.  The purified plasmid DNA was digested via restriction enzymes SwaI and AgeI. This digest 
was analyzed by electrophoresis on a 1% agarose gel to confirm the presence of the gene block in 
the viral plasmid. DNA sequence analysis of the plasmid was used to confirm the presence of the 
desired structure disrupting mutations and throughout the remainder of the gene block, past the 
SwaI/AgeI restriction enzyme sites.  
Generating Virus 
 The sequence-confirmed plasmid DNA was linearized using NotI-HF (NEB) digest and 
purified by phenol chloroform extraction and ethanol precipitation. The viral plasmid contains an 
SP6 promoter so RNA was generated using an Ambion mMessage mMachine SP6 RNA 
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Transcription kit (Thermo Fisher). To confirm the presence of RNA, the transcription reaction 
product was run on a 1% agarose gel. 10µg of naked RNA was electroporated into 1.0x107 BHK-
21 cells to generate virus. After electroporation, the treated cells were cultured at 37°C for 36 
hours. Cell culture supernatant containing virus was harvested, aliquoted for further experiments, 
and stored at -80°C.   
Specific Infectivity Assay 
An aliquot of electroporated BHK-21 cells for generating virus was used for a specific 
infectivity assay. 50µL of cells electroporated with the viral RNA were serially diluted (dilutions 
from 10 to 106, in 1:10 dilution steps) and 250µL of each dilution were plated onto a monolayer 
of Vero81 cells (~70% confluent at the time of the specific infectivity assay). The monolayers 
were rocked every 15 minutes for 1.5 hours after the initial infection to prevent the monolayer 
from drying out. Then monolayers were covered in 4mL of overlay (1:1 ratio complete media and 
2.5% carboxymethyl cellulose) to prevent the virus from moving between cells. Virus was allowed 
to form plaques for 3 days, after which the cells were fixed with 4% paraformaldehyde and stained 
with 0.25% crystal violet overnight. The resulting plaques were counted to determine the number 
of cells that were successfully electroporated with infectious RNA to determine the RNA 
infectivity efficiency.  
Plaque Assay 
Infectious virus was quantified by plaque assay. 50µL of 181/25 wild type and T19 were 
serially diluted from 100 to 107 (a 1:10 dilution each time) and 200µL of each dilution were plated 
onto a monolayer of Vero81 cells in technical duplicate. Plates were rocked every 15 minutes for 
1 hour after the inoculum was placed in each well to allow for the attachment and entry of the virus 
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into the cells and to prevent the monolayer from drying out and then each monolayer was covered 
in 2 mL of overlay (1:1 complete media and 2.5% CMC) to prevent the virus from moving between 
cells. After 72 hours, cells were fixed with 4% paraformaldehyde and then stained with 2.5% 
crystal violet overnight. The plaques were counted and plaque forming units per mL (PFU/mL) 
was calculated. 
Virus Growth Curves 
 To assess viral replication up to 72 hours, growth curves were performed. 6 well plates 
were seeded with 3x106  Vero81 cells per well 24 hours before infection as to be 75-80% confluent 
at the time of the initial infection. These cells were infected with an MOI of 0.01, calculated by:  
𝐶𝑒𝑙𝑙𝑠 𝑝𝑒𝑟 𝑤𝑒𝑙𝑙 𝑋 𝑀𝑂𝐼
𝑠𝑡𝑜𝑐𝑘 𝑣𝑖𝑟𝑢𝑠 𝑡𝑖𝑡𝑒𝑟 (𝑃𝐹𝑈/𝑚𝐿)
 𝑥 1000 𝑥 # 𝑜𝑓 𝑤𝑒𝑙𝑙𝑠 𝑡𝑜 𝑖𝑛𝑓𝑒𝑐𝑡 =  𝑥 𝜇𝐿 𝑣𝑖𝑟𝑢𝑠 𝑠𝑡𝑜𝑐𝑘 𝑛𝑒𝑒𝑑𝑒𝑑  
Inoculum was prepared by diluting virus stock 1:100 in order to have a volume greater than 30 μL 
and combined with dilution media (PBS with 2% FBS and Ca/Mg) to reach a total of 400 μL of 
inoculum per well to be infected. Three wells per virus were infected with 400 μL of inoculum and 
incubated at 37°C for 1 hour with rocking every 15 minutes to prevent drying of the monolayer. 
After incubation the cells were washed 3 times with 1 mL of cold PBS. 4 mL of Vero81 media 
were added to each well and a 100 μL aliquot was collected and stored at -80C for the 0 hour time 
point. The 100 μL volume was replaced with cell media after collection. The collection process 
was repeated at 6, 12, 24, 36, 48, and 72 hours post infection. The collected samples were titered 
using a plaque assay as described above.  PFU/mL was plotted over time to assess virus replication. 
Growth curves were repeated using mosquito cells, C6/36, which were seeded with 1x106 cells per 
well 24 hours before the initial infection.  
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Results 
 
SHAPE-MaP analysis identifies novel RNA secondary structures  
 
Of the novel, highly stable RNA secondary structures that were identified through SHAPE-
MaP, this project specifically investigates the effects of mutant 181/25 T19. The sequence 
underlying this stem loop is highly conserved between CHIKV strains and is located at the coding 
region of the cleavage site between nsP2 and nsP3 (Figure 2). The structure disruption mutant of 
this structure contains five point mutations in the stem loop (Figure 1A), and the resulting disrupted 
structure can be seen in Figure 1B.   Although the single nucleotide changes result in a disruption 
of the structure, they were done so that the coding sequence did not result in any changes in the 
triplicate coding of the amino acids so that the effect that structure has on function can be assessed 
independent of coding changes. This stem loop was specifically investigated because of its unique 
location in the genome. The N-terminal domain of nsP3 is highly conserved among strains, and 
the nsp2 C-terminal domain is known to have an impact on regulating minus-strand synthesis and 
cleaving the nonstructural viral proteins into the intermediate and final protein products4. As this 
stem loop is highly conserved between strains, mutants affecting this structure may impact viral 
replication. 
9 
 
A)             B)  
Figure 1: Structural Mutant 181/25 T19. A) This image on the left shows the original RNA 
secondary structure of T19 including the five point mutations that have been inserted into the stem 
loop of structure T19 (shown in green stars). B) The image on the right is the predicted disrupted 
T19 RNA secondary structure after the mutations were implemented, the T19 stem loop is shown 
in the red box.  
 
 
Figure 2: 181/25 T19 Mutant Location in the Genome. This image highlights where mutant T19 
is located within the 181/25 genome. It is between nsP2 and nsP3 and is depicted by the orange 
square within the red box.  
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Specific infectivity assays show no significant impact RNA infectivity  
Since the effects of RNA secondary structure in the coding regions of CHIKV are largely 
unknown, we wanted to assess the infectivity of the naked RNA of the structural mutants compared 
to that of wildtype 181/25. Specific infectivity assays were performed to determine the number of 
infectious centers that were formed as RNA produced virus. This allowed us to calculate the 
number of cells that were successfully infected with RNA (Table 1). By comparing the number of 
infectious centers across experiments, we can see that there is no statistical difference in the 
infectivity of wildtype compared to that of the structural mutant T19 (Figure 3).  
 
Virus Dilution Plaques 
Number of cells 
successfully 
electroporated 
181/25 T19-1* 1000 31 620000 
181/25 T19-2 10000 19 3800000 
181/25 T19-3 1000 60 1200000 
181/25 WT-1* 1000 28 560000 
181/25 WT-2 10000 48 9600000 
181/25 WT -3 1000 11 220000 
 
Table 1: Specific Infectivity Assay Results. The data shown is from three separate 
electroporations and specific infectivity assays that tested 181/25 WT and 181/25 T19. Plaques 
were counted and the number of cells that were successfully electroporated were calculated. *The 
assay for electroporation one was plated with BHK-21 cells rather than Vero81 cells, and the 
plaques were larger than expected.  
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Figure 3: Specific Infectivity Infectious Centers. The data shown is from three independent 
experiments. The impacts of the mutations on early replication from infection with naked RNA 
were tested and compared to that of wild type 181/25. The mutants showed no significant 
difference using a student’s t-test. Error bars represent standard deviation.  
 
Plaque assays determine no difference in virus yield 
With the harvested virus from the electroporations above, plaque assays were performed 
in order to determine the virus titer (plaques forming units per mL) of each sample for use in future 
experiments (Table 2) 
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Virus Sample  Average Plaque 
Forming Units 
(PFU/mL) 
181/25 T19 Stock 1  4.4 x 108 
181/25 WT Stock 1 3.025 x 108 
181/25 T19 Stock 2 5.975 x 108 
181/25 WT Stock 2 5.5 x 107 
181/25 T19 Stock 3 1.65 x 107 
181/25 WT Stock 3 1.35 x 107 
 
Table 2: Plaque Assay Titers. This data is averaged from duplicate plaque assays for each virus 
stock. Calculation: PFU/mL =  (Plaques) × (5) × (dilution factor) 
 
Figure 4: Plaque Assay Titer. This graph shows the average PFU/mL (Log10) for each of the 
harvested virus socks (See Table 2).  
Wt T19
0
2
4
6
8
10
Virus
A
v
e
ra
g
e
 P
F
U
/m
L
 (
L
o
g
1
0
)
Plaque Assay Titer
13 
 
Mutated RNA had no effect on viral replication  
 To further characterize the role of RNA secondary structures on viral replication, we 
performed virus growth curves looking at virus replication over a span of 48 to 72 hours in either 
mammalian (Vero81) or insect (C6/36) cells. In addition to T19, other structure mutants were 
created from the novel 18 structures identified through SHAPE-MaP, and although they are not 
discussed in this project, structure mutants T25 and T2.1 are included in these graphs as they were 
tested in the same experiment. These growth curves show that the mutated RNA, resulting in an 
altered RNA secondary structure, had no impact on viral replication.  
 
Figure 5: C6/36 Growth Curve This graph represents the viral replication over 48 hours of 
181/25 Wildtype compared to structural mutants T19, T25, and T2.1 in mosquito cells (C6/36). 
Data represents the average of biological triplicates.  
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Figure 6: Vero81 Growth Curve This graph represents the viral replication over 48 hours of 
181/25 Wildtype compared to structural mutants T19 and T25 in mammalian Vero81 cells. Data 
represents the average of biological triplicates. 
Discussion  
 CHIKV currently has no licensed vaccines or specific treatments; however, little work has 
been done to determine the role that the viral RNA itself has on viral replication, infectivity, and 
thereby pathogenesis. Using SHAPE-MaP, we identified 18 novel, highly stable structures in the 
coding region of the genome that were not yet previously described. To better understand the role 
that these RNA structures play, we made structure mutants to assess the impact that these RNA 
structures have on RNA infectivity and virus replication. 
At this time, neither mutant T19, nor any of the other structure mutants, appear to be 
necessary for virus replication in interferon-deficient mammalian and mosquito cells or affect 
RNA infectivity. In regards to the specific infectivity assay, there is no statistically significant 
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difference between the log10 of infectious centers of wildtype 181/25 compared to that of T19 
when three independent experiments are averaged (Figure 3). This indicates that the mutations had 
no impact on RNA infectivity compared to that of wildtype.  
These structure mutants do not exhibit any replication phenotype as tested by virus growth 
curves in either mammalian cells (Vero81) or mosquito cells (C6/36). In mosquito cells (C6/36), 
which is the virus vector, the mutants shows no inhibition of replication compared to that of 
wildtype (Figure 4). The same result was observed in the growth curves performed in mammalian 
cells (Vero81), where there is no significant difference between the replication curves of the 
mutants compared to wildtype.  
 To further characterize the impact of these RNA structure mutants, further tests will be 
necessary. The mammalian and mosquito cells lines (Vero81 and C6/36) that were used have 
mutations that prevent them from mounting an innate immune defense against the virus, as they 
are interferon deficient. Additional tests will assess immune competent cell lines to test the 
replication of each individual structure disruption mutant to see if the mutations impact or interact 
with the innate immune system. Competition studies will determine if when in direct competition 
any of the structural mutants can outcompete wildtype or other structure mutants. Further, it would 
be beneficial to re-sequence and reanalyze the mutant virus after generation using SHAPE-MaP to 
ensure that the desired changes in RNA structure are still present and that they were not corrected 
or suppressed by the occurrence of other mutations by early replication mechanisms, which would 
result in the mutant phenotypes appearing to be consistent with that of wild type.  
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